Because serum tumor necrosis factor (TNF) is high in patients with Kawasaki disease (KD), infliximab, an anti-TNF agent, has been proposed as a potential treatment for refractory KD, but few randomized trials have been conducted to demonstrate the efficacy and safety of using infliximab in this setting.
Kawasaki disease (KD), an acute febrile disorder that primarily affects children aged 5 years or younger and can cause coronary artery abnormalities and acquired heart disease in children. Suppressing acute inflammation within 10 days of the disease’s onset is critical to preventing coronary artery lesions (CAL) in these patients.
While intravenous immunoglobulin (IVIG) is the initial therapy for KD, and typically leads to rapid defervescence (and therefore lower incidence of CALs), approximately 20% of patients do not respond adequately to IVIG. Often, IVIG-refractory KD is treated with an additional dose of IVIG, though half of refractory patients may not respond to the added dose.
Because serum tumor necrosis factor (TNF) is high in patients with KD, infliximab, an anti-TNF agent, has been proposed as a potential treatment for IVIG-refractory KD, but few randomized trials have been conducted to demonstrate the efficacy and safety of using infliximab in this setting.
Results of a small study of infliximab versus an additional dose of IVIG for treatment-refractory patients with KD, recently published in Scientific Reports, showed that infliximab improved the defervescence rate within 48 hours compared to treatment with IVIG, and that infliximab was well tolerated.
The study began on May 2012 and ended in September 2014. Because only a small group of patients met eligibility criteria, the recruitment target was not reached. In total, 31 patients were enrolled and randomized to receive either infliximab in a single intravenous dose of 5 mg/kg (n = 16) or intravenous polyethylene glycol-treated human immunoglobulin (VGIH) at a dose of 2 mg/kg (n = 15). The study’s primary outcome was the defervescence rate within 48 hours after treatment, and safety was evaluated through day 56.
The researchers found that:
The study’s authors say that, as prevention of CALs is among the most important goals of treating KD, and as anti-TNF therapy directly improves endothelial cell function and reduces inflammation, treating KD with infliximab may contribute to preventing development of coronary artery abnormalities. Larger and longer studies may help to confirm these trial results and provide longer-term outcomes with infliximab.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.